Traj45: A Protein Essential for T Cell Regulation and Immune System Development

Target Name: TRAJ45

NCBI ID: G28710

TRAJ45

Other Name(s): T cell receptor alpha joining 45

Traj45: A Protein Essential for T Cell Regulation and Immune System Development

Traj45, also known as T cell receptor alpha joining 45, is a protein that plays a crucial role in the development and regulation of T cells, which are a vital part of the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, and their activity is tightly controlled by a complex network of signals and interactions. Traj45 is one of the key proteins that helps to coordinate these interactions, and its dysfunction has been linked to a number of diseases.

The T cell receptor alpha joining 45 protein is a type of transmembrane protein that is composed of four extracellular domains and a transmembrane region. It is expressed in many different tissues throughout the body, including the skin, hair, and nails, as well as the lymphoid organs and other tissues. Traj45 is characterized by its ability to form a complex with the protein PD-L1, which is a negative regulator of T cell proliferation and activation.

The PD-L1-Tj45 interaction is a critical part of the regulation of T cell activity. PD-L1 can inhibit the activity of Traj45, preventing it from forming the complex with PD-L1 that is necessary for T cell activation. However, Traj45 can also activate PD-L1, which in turn can enhance the inhibition of PD-L1 by PD-L1-Tj45. This complex interplay between PD-L1 and Traj45 is critical for the regulation of T cell activity and the development of an immune response.

In addition to its role in T cell regulation, Traj45 is also involved in the development and maintenance of the immune system. It has been shown to play a key role in the development of CD4+ T cells, which are a crucial part of the immune system. Traj45 has also been shown to be involved in the regulation of T cell memory and tolerance, as well as the development of autoimmune diseases.

Dysfunction of Traj45 has been linked to a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. For example, studies have shown that Traj45 dysfunction is associated with an increased risk of cancer, both in humans and in animal models. In addition, Traj45 has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Furthermore, Traj45 has also been linked to the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Studies have shown that Traj45 dysfunction is associated with the development of these disorders, and that modulating Traj45 activity may be a potential therapeutic approach.

In conclusion, Traj45 is a protein that plays a critical role in the development and regulation of T cells, as well as the immune system. Its dysfunction has been linked to a number of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. Therefore, Traj45 may be a promising drug target or biomarker for the development of new therapies for these diseases.

Protein Name: T Cell Receptor Alpha Joining 45

The "TRAJ45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets